eCysticFibrosis Review
ETI (CFTR Triple Therapy): Clinical Opportunities
September 14, 2022
The advent of triple CFTR modulator therapy ETI (elexacaftor/tezacaftor/ivacaftor) poses a number of clinical questions. Are three agents really better than two? For which patients, in what circumstances? What does the CF Team need to understand to en
New York City
ECysticFibrosis Review podcast channel
Visit Podcast Website
RSS Podcast Feed
Subscribe
Share
Add to MyCast